Schizophrenia | Disease Landscape & Forecast | G7 | 2023
The schizophrenia therapy market is crowded and dominated by atypical and typical antipsychotics. Although the continued generic erosion of oral atypical antipsychotics influences psychiatrists’ treatment decisions (e.g., the recent availability of generic lurasidone in the United States), newer oral atypical antipsychotics (e.g., Alkermes’s Lybalvi, Intra-Cellular Therapies’ Caplyta), along with drugs such as BioXcel Therapeutics’ Igalmi, are aiming to make inroads into the treatment pathway. Competition between long-acting injectables (LAIs) is also intensifying with the availability of new therapies (e.g., Janssen’s Invega Hafyera, Lundbeck / Otsuka’s Abilify Asimtufii, Teva’s Uzedy), along with the generic availability of some key LAIs. Nevertheless, novel drugs targeting key unmet needs will be welcomed (e.g., Boehringer Ingelheim’s iclepertin for cognitive impairment in schizophrenia, Acadia’s Nuplazid for the negative symptoms of schizophrenia), but other therapies either in preregistration or late-phase development (e.g., Karuna’s KarXT, Newron Pharmaceuticals’ evenamide) will have to clearly differentiate themselves from established therapies to gain a strong foothold in this market. As such, a deep understanding of the current and future dynamics of the schizophrenia therapy market is critical.
Questions answered
- What is the current size of the schizophrenia market in the G7 countries? What key events will influence the market over the next decade?
- What factors drive and constrain the use of newer-to-market oral and LAIs of atypical antipsychotics? How is competition heating up in these segments?
- What are the areas of highest unmet need in schizophrenia treatment? Which late-phase therapies have the potential to fulfill these needs?
- What improvements would key late-phase therapies need to demonstrate in order to compete effectively in this crowded market? How will these agents be placed in the schizophrenia treatment algorithm?
Geographies: United States, EU5, Japan
Primary research: 33 country-specific interviews with thought-leading psychiatrists, supported by survey data collected for this and other Clarivate research
Epidemiology: Diagnosed prevalence of schizophrenia by country, segmented by positive symptoms, negative symptoms, and cognitive impairment; drug-treated prevalence of schizophrenia by country
Forecast: 10-year, annualized, drug-level sales and patient share of key schizophrenia therapies through 2032, segmented by brands/generics
Emerging therapies: Phase 3 / PR: 11 drugs; coverage of select early-phase products
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution enhancements
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Additionally, Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
